Bio-Rad Laboratories has reached a settlement agreement with bioMerieux resolving various licensing disputes between the two companies
The licensing disputes were originally between bioMerieux and Pasteur Sanofi Diagnostics (PSD) and were part of Bio-Rad's acquisition of PSD in 1999.
Additionally, bioMerieux has granted Bio-Rad a license under its Epstein-Barr virus patent rights.
As a result of the settlement, Bio-Rad anticipates a one-time impact on its diagnostics revenue of an additional $10 to $12 million in the second quarter of 2006.
"We are pleased that these disputes have been resolved," said John Goetz, Bio-Rad vice president and group manager of clinical diagnostics.
"In addition, gaining access to the Epstein-Barr virus fits in well with our overall strategy for multiplexing panels that are used with our Bio-Plex 2200 system, which is able to generate multiple results from a single patient sample."
